Raidium Launches Revolutionary AI Imaging Workflow for Oncology in US Cancer Centers
In a groundbreaking move, Raidium, the AI-native radiology company, announced the U.S. launch of its AI-powered imaging solution, Raidium Read (R.Read). This new tool is specifically designed to transform how cancer centers handle imaging reviews. The initial deployment of this technology is at the renowned Moffitt Cancer Center, chosen to enhance its imaging capabilities and replace outdated radiomics tools. R.Read promises to deliver advanced features such as entire body lesion detection, AI segmentation models, and the ability to follow lesions over time, addressing the complexities involved in oncology imaging workflows.
As the fight against cancer evolves, the necessity for precise and early lesion detection has never been more critical. Recent studies indicate that timely identification of lesions can help many patients avoid the need for surgery. The World Health Organization is also laying the groundwork for enhanced guidelines concerning early screening and detection of precancerous lesions. Clinicians and hospital administrators are on the lookout for efficient tools that can assist them in this essential task, identifying lesions earlier and facilitating quicker action.
Radiology has the potential to play a pivotal role in these efforts, especially as AI technology continues to redefine its applications. Over 70% of FDA-approved AI-enabled medical devices fall under the radiology category, yet the integration of these tools into everyday workflows has been less than smooth. Current AI solutions often add complexity to an already busy reading room, increasing the workload for radiologists and leading to a survey indicating that 41% of radiologists feel existing AI tools fail to meet their practical needs.
The innovative design of Raidium's technology stands apart from previous AI integrations. Rather than attempting to layer AI onto existing outdated systems, Raidium has developed its AI-native viewer from scratch, specifically tailored to meet the needs of real-world radiologists. This integrated solution minimizes friction and increases usability, bringing all aspects of complex oncology reviews into a unified clinical environment. The debut of R.Read in the U.S. showcases how Raidium is setting a new standard in the field, focusing initially on oncology follow-ups where no effective AI solutions had previously existed.
"For two decades, conventional PACS viewers have resisted necessary changes, and AI's initial limitations couldn't keep pace with advancements in technology. Yet, agentic AI is now instigating a quiet revolution by offering seamless incorporation of user-friendly features and advanced reasoning to redefine the reading room experience," said Paul Herent, MD, CEO and Co-Founder of Raidium. "By focusing on oncology follow-ups, we aim to solve a complex workflow that has long plagued cancer centers, ultimately saving radiologists' time and reducing repetitive tasks."
The features of R.Read highlight its practicality in oncology imaging settings, where efficiency is vital:
Dr. Cesar Lam from Moffitt Cancer Center praised Raidium's holistic approach, stating, "This technology allows us to explore ambitious research projects that once seemed unattainable. It is radically transforming how we conduct oncology clinical research, providing us with tools designed specifically for the intricate landscape of real-world imaging data."
Currently available for clinical trial and oncology research purposes, R.Read is eagerly awaiting final regulatory approvals before it can be widely used in everyday clinical settings. Raidium is in the process of securing 510(k) clearance for particular features, with an announcement expected before the close of 2026. Ideally, this innovation will allow oncology centers to commence operations immediately, eliminating integration complications and facilitating a smoother transition into existing workflows. Qualified cancer centers can register on Raidium's official website to gain access to this promising technology.
Raidium is committed to empowering radiologists by developing a suite of tools that cater to their specific needs. By merging exceptional foundational model research capabilities with an AI-driven, streamlined viewer system, Raidium successfully automates many complex processes while keeping radiologists firmly in control, thus enhancing the overall quality and efficiency of cancer care.
As the fight against cancer evolves, the necessity for precise and early lesion detection has never been more critical. Recent studies indicate that timely identification of lesions can help many patients avoid the need for surgery. The World Health Organization is also laying the groundwork for enhanced guidelines concerning early screening and detection of precancerous lesions. Clinicians and hospital administrators are on the lookout for efficient tools that can assist them in this essential task, identifying lesions earlier and facilitating quicker action.
Radiology has the potential to play a pivotal role in these efforts, especially as AI technology continues to redefine its applications. Over 70% of FDA-approved AI-enabled medical devices fall under the radiology category, yet the integration of these tools into everyday workflows has been less than smooth. Current AI solutions often add complexity to an already busy reading room, increasing the workload for radiologists and leading to a survey indicating that 41% of radiologists feel existing AI tools fail to meet their practical needs.
The innovative design of Raidium's technology stands apart from previous AI integrations. Rather than attempting to layer AI onto existing outdated systems, Raidium has developed its AI-native viewer from scratch, specifically tailored to meet the needs of real-world radiologists. This integrated solution minimizes friction and increases usability, bringing all aspects of complex oncology reviews into a unified clinical environment. The debut of R.Read in the U.S. showcases how Raidium is setting a new standard in the field, focusing initially on oncology follow-ups where no effective AI solutions had previously existed.
"For two decades, conventional PACS viewers have resisted necessary changes, and AI's initial limitations couldn't keep pace with advancements in technology. Yet, agentic AI is now instigating a quiet revolution by offering seamless incorporation of user-friendly features and advanced reasoning to redefine the reading room experience," said Paul Herent, MD, CEO and Co-Founder of Raidium. "By focusing on oncology follow-ups, we aim to solve a complex workflow that has long plagued cancer centers, ultimately saving radiologists' time and reducing repetitive tasks."
The features of R.Read highlight its practicality in oncology imaging settings, where efficiency is vital:
- - Reduced manual effort: Streamlined processes across search, review, and follow-up tasks.
- - Diminished variability: Inter-reader inconsistency can be reduced significantly through automated measurements modeled to enhance reliability.
- - Longitudinal tracking: Enhanced ease of tracking lesions through clinical trials and cancer care routines.
- - Lowered documentation burden: Ensuring that radiologists maintain oversight with less paperwork and administrative hassle.
- - Improved communication: Effective channels for radiologist-clinician interaction, crucial for timely medical decision-making (e.g., tumor boards).
Dr. Cesar Lam from Moffitt Cancer Center praised Raidium's holistic approach, stating, "This technology allows us to explore ambitious research projects that once seemed unattainable. It is radically transforming how we conduct oncology clinical research, providing us with tools designed specifically for the intricate landscape of real-world imaging data."
Currently available for clinical trial and oncology research purposes, R.Read is eagerly awaiting final regulatory approvals before it can be widely used in everyday clinical settings. Raidium is in the process of securing 510(k) clearance for particular features, with an announcement expected before the close of 2026. Ideally, this innovation will allow oncology centers to commence operations immediately, eliminating integration complications and facilitating a smoother transition into existing workflows. Qualified cancer centers can register on Raidium's official website to gain access to this promising technology.
Raidium is committed to empowering radiologists by developing a suite of tools that cater to their specific needs. By merging exceptional foundational model research capabilities with an AI-driven, streamlined viewer system, Raidium successfully automates many complex processes while keeping radiologists firmly in control, thus enhancing the overall quality and efficiency of cancer care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.